CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Abstract
The striking and unexpected relative risk reductions in cardiovascular (CV) mortality (38%), hospitalization for heart failure (35%), and death from any cause (32%) observed in the EMPA-REG OUTCOME trial using an inhibitor of sodium–glucose cotransporter 2 (SGLT2) in patients with type 2 diabetes and high CV risk have raised the possibility that mechanisms other than those observed in the trial—modest improvement in glycemic control, small decrease in body weight, and persistent reductions in blood pressure and uric acid level—may be at play. We hypothesize that under conditions of mild, persistent hyperketonemia, such as those that prevail during treatment with SGLT2 inhibitors, β-hydroxybutyrate is freely taken up by the heart (among other organs) and oxidized in preference to fatty acids. This fuel selection improves the transduction of oxygen consumption into work efficiency at the mitochondrial level. In addition, the hemoconcentration that typically follows SGLT2 inhibition enhances oxygen release to the tissues, thereby establishing a powerful synergy with the metabolic substrate shift. These mechanisms would cooperate with other SGLT2 inhibition–induced changes (chiefly, enhanced diuresis and reduced blood pressure) to achieve the degree of cardioprotection revealed in the EMPA-REG OUTCOME trial. This hypothesis opens up new lines of investigation into the pathogenesis and treatment of diabetic and nondiabetic heart disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
How mitochondria produce reactive oxygen species
Murphy, M. P. (2009) · Biochemical Journal · doi:10.1042/bj20081386 · Cited by 8,207 · cited 1×
“Furthermore, a persistently elevated rate of FFA oxidation generates reactive oxygen species in excess of scavenging capacity (42); the resulting oxidative stress contributes to mitochondrial damage in a range of pathologies (43).”
BackgroundESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012
Authors/Task Force Members, McMurray, J. J. V., Adamopoulos, S., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., Falk, V., Filippatos, G., Fonseca, C., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs104 · Cited by 6,879
Eplerenone in patients with systolic heart failure and mild symptoms
Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009492 · Cited by 3,111
Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS
Chouchani, E. T., Pell, V. R., Gaude, E., Aksentijević, D., Sundier, S. Y., Robb, E. L., Logan, A., Nadtochiy, S. M., Ord, E. N. J., Smith, A. C., et al. (2014) · Nature · doi:10.1038/nature13909 · Cited by 2,907 · cited 1×
“perfusion injury (53)dconverge on insufficient mitochondrial energy output and contractile failure as the basic mechanism.”
BackgroundESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012
Authors/Task Force Members, McMurray, J. J. V., Adamopoulos, S., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., Falk, V., Filippatos, G., Fonseca, C., et al. (2012) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfs105 · Cited by 2,644
The Failing Heart — An Engine Out of Fuel
Neubauer, S. (2007) · New England Journal of Medicine · doi:10.1056/nejmra063052 · Cited by 2,417
Myocardial Fatty Acid Metabolism in Health and Disease
Lopaschuk, G. D., Ussher, J. R., Folmes, C. D. L., Jaswal, J. S., & Stanley, W. C. (2010) · Physiological Reviews · doi:10.1152/physrev.00015.2009 · Cited by 2,179
Myocardial Substrate Metabolism in the Normal and Failing Heart
Stanley, W. C., Recchia, F. A., & Lopaschuk, G. D. (2005) · Physiological Reviews · doi:10.1152/physrev.00006.2004 · Cited by 2,048 · cited 1×
“and functional manifestation (reduced or preserved ejection fraction) (51).”
Background
Cited by
Items 501–600 of 1,000
Effects of SGLT2 inhibitors on cardiac structure and function
Novo, G., Guarino, T., Lisi, D. D., Biagioli, P., & Carluccio, E. (2022) · Heart Failure Reviews · doi:10.1007/s10741-022-10256-4 · Cited by 17
Ketogenic Diet Regulates Cardiac Remodeling and Calcium Homeostasis in Diabetic Rat Cardiomyopathy
Lee, T.-I., Trang, N. N., Lee, T., Higa, S., Kao, Y., Chen, Y., & Chen, Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216142 · Cited by 20
“Moreover, increased circulating ketone levels in patients with heart failure may also improve their cardiac health [4,6] because, as oxygen-efficient, highly energetic fuel, ketone bodies may enhance the work capacity of the myocardium at risk [7,8].”
BackgroundLeveraging metabolism for better outcomes in heart failure
Ng, Y. H., Koay, Y. C., Marques, F. Z., Kaye, D. M., & O’Sullivan, J. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae216 · Cited by 20
Balijepalli, C., Shirali, R., Kandaswamy, P., Ustyugova, A., Pfarr, E., Lund, S. S., & Druyts, E. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0456-7 · Cited by 17
Metabolic remodeling induced by mitokines in heart failure
Duan, J., Chen, Z., Wu, Y., Zhu, B., Yang, L., & Yang, C. (2019) · Aging · doi:10.18632/aging.102247 · Cited by 17
Coleman, R. L., Gray, A. M., Broedl, U. C., FITCHETT, D. H., George, J. T., Woerle, H. J., Zinman, B., & Holman, R. R. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14017 · Cited by 17
Shin, Y., Moon, J. H., Chin, H. J., Ferrannini, E., & Lim, S. K. (2020) · Endocrinology and Metabolism · doi:10.3803/enm.2020.35.2.329 · Cited by 19
Self-citationQu, W., Li, Y., Liu, X., Xu, T., & Tian, B. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.630820 · Cited by 18
“It has been suggested that the increase in hematocrit may contribute to the cardioprotective effect of these drugs by increasing the oxygen-carrying capacity (Ferrannini et al., 2016; Lytvyn et al., 2017).”
BackgroundPetrov, M. S. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1931118 · Cited by 18
Empagliflozin as a new management strategy on outcomes in patients with type 2 diabetes mellitus
Салухов, В. В., & Demidova, T. Y. (2016) · Diabetes Mellitus · doi:10.14341/dm8216 · Cited by 21
Lioudaki, E., Androulakis, E. S., Whyte, M., Stylianou, K., Daphnis, E., & Ganotakis, E. S. (2017) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-017-6724-3 · Cited by 18
Jespersen, N. R., Lassen, T. R., Hjortbak, M. V., Støttrup, N. B., & Bøtker, H. E. (2017) · Cardiovascular Pharmacology Open Access · doi:10.4172/2329-6607.1000210 · Cited by 17
Cersósimo, E., & Miles, J. M. (2018) · Current Diabetes Reviews · doi:10.2174/1573399814666180813124645 · Cited by 18
Spontaneous ketonuria and risk of incident diabetes: a 12 year prospective study
Kim, G., Lee, S., Lee, B., Kang, E. S., Soo, B., Ferrannini, E., Lee, Y., & Cho, N. H. (2019) · Diabetologia · doi:10.1007/s00125-019-4829-x · Cited by 19
Self-citationKetone body metabolism in diabetic and non-diabetic heart failure
Qian, N., & Wang, Y. (2019) · Heart Failure Reviews · doi:10.1007/s10741-019-09857-3 · Cited by 18
Cardiovascular effects and mechanisms of sodium‐glucose cotransporter‐2 inhibitors
Yang, F., Meng, R., & Zhu, D. (2020) · Chronic Diseases and Translational Medicine · doi:10.1016/j.cdtm.2020.07.002 · Cited by 19
SGLT2 Inhibition in Heart Failure with Preserved Ejection Fraction — The New Frontier
Aguiar‐Neves, I., Santos‐Ferreira, D., & Fontes‐Carvalho, R. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2401001 · Cited by 16
“Another proposed mechanism of SGLT2 inhibition on cardiomyocytes relates to their potential beneficial effects on mitochondrial function [142,143].”
BackgroundSeefeldt, J. M., Libai, Y., Berg, K., Jespersen, N. R., Lassen, T. R., Dalsgaard, F. F., Ryhammer, P. K., Pedersen, M., Ilkjær, L. B., Hu, M. A., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-51387-y · Cited by 18
“This may support the hypothesis that ketones serve as alternative energy substrates during ischemic stress 42,43 .”
Ketones provide an extra source of fuel for the failing heart without impairing glucose oxidation
Pherwani, S., Connolly, D., Sun, Q., Karwi, Q. G., Carr, M., Ho, K. L., Wagg, C. S., Zhang, L., Levasseur, J. L., Silver, H. L., et al. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155818 · Cited by 17
Madonna, R., Biondi, F., Alberti, M., Ghelardoni, S., Mattii, L., & D’Alleva, A. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116650 · Cited by 19
Voorrips, S. N., Palm, C. L., Saucedo‐Orozco, H., Mahmoud, B., Schouten, E. M., Feringa, A. M., Sánchez-Aguilera, P., Nijholt, K. T., Yurista, S. R., van der Meer, P., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3633 · Cited by 19
“6,7 SGLT2i have been shown to further increase circulating ketones and their beneficial effects have been linked to cardiac ketone body oxidation by several groups, 3,8,9 but this association is disputed by others.”
Mortality Reduction in EMPA-REG OUTCOME Trial: Beyond the Antidiabetes Effect
Suissa, S. (2018) · Diabetes Care · doi:10.2337/dc17-1059 · Cited by 16
Yan, C., Thijs, L., Cao, Y., Trenson, S., Zhang, Z., Janssens, S. P., Staessen, J. A., & Feng, Y. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.14791 · Cited by 20
Sodium-Glucose Cotransporter-2 Inhibitors in Vascular Biology: Cellular and Molecular Mechanisms
Xiao, L., Nie, X., Cheng, Y., & Wang, N. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07216-9 · Cited by 16
Sodium-glucose cotransporter 2 inhibitors as the first universal treatment of chronic kidney disease
Din, U. A. S. E., Salem, M. M., & Abdulazim, D. O. (2021) · Nefrología (English Edition) · doi:10.1016/j.nefro.2021.03.014 · Cited by 18
Nakatsukasa, T., Ishizu, T., Ouchi, M., Murakoshi, N., Sato, K., Yamamoto, M., Kawanishi, K., Seo, Y., & Ieda, M. (2022) · Circulation Journal · doi:10.1253/circj.cj-22-0105 · Cited by 18
Lin, Y., Cai, Z., Yuan, J., Liu, H., Pang, X., Chen, Q., Tang, X., Geng, Q., & Dong, S. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01679-2 · Cited by 17
Pancholia, A. K. (2018) · Indian Heart Journal · doi:10.1016/j.ihj.2018.08.022 · Cited by 18
Ojha, U., Reyes, L. M., Eyenga, F., Oumbe, D., Watkowska, J., & Saint-Jacques, H. (2021) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-021-00486-6 · Cited by 17
SGLT-2 Inhibitors in Heart Failure: Implications for the Kidneys
Verbrugge, F. H., Martens, P., & Müllens, W. (2017) · Current Heart Failure Reports · doi:10.1007/s11897-017-0345-9 · Cited by 18
Empagliflozin in patients with type 2 diabetes mellitus and chronic obstructive pulmonary disease
Anker, S. D., Sander, L. E., FITCHETT, D. H., Zinman, B., Ofstad, A. P., Wanner, C., Vedin, O., Lauer, S., Verma, S., Yaggi, H. K., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109837 · Cited by 15
Cardiovascular disease leads to a new algorithm for diabetes treatment
Rodriguez, V., Weiss, M. C., WEINTRAUB, H. S., Goldberg, I. J., & Schwartzbard, A. Z. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.07.004 · Cited by 16
The optimal blood pressure target in diabetes mellitus: a quest coming to an end?
Papadopoulou, E., Angeloudi, E., Karras, S. Ν., & Sarafidis, P. A. (2018) · Journal of Human Hypertension · doi:10.1038/s41371-018-0079-5 · Cited by 17
Willis, M. S., Asseburg, C., Nilsson, A., & Neslusan, C. A. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00681-4 · Cited by 16
Impact of Sodium–Glucose Co-Transporter 2 Inhibitors on Cardiac Protection
Wu, V. C., Li, Y., & Wang, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22137170 · Cited by 17
Growing role of SGLT2i in heart failure: evidence from clinical trials
Varadhan, A. K., Stephan, K., Gupta, R., Vyas, A. V., Ranchal, P., Aronow, W. S., Hawwa, N., & Lanier, G. M. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2051480 · Cited by 15
Succurro, E., Vizza, P., Papa, A., Miceli, S., Cicone, F., Fiorentino, T. V., Sciacqua, A., Andreozzi, F., Veltri, P., Cascini, G. L., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14816 · Cited by 16
SGLT2 inhibition reduces myocardial oxygen consumption
Søndergaard, E., Lauritzen, E. S., Lauritsen, K. M., Åkerblom, A., Nuutila, P., Oldgren, J., & Gormsen, L. C. (2022) · Metabolism Open · doi:10.1016/j.metop.2022.100207 · Cited by 15
Diastolic function in chronic kidney disease
SIMONE, G. D., & Mancusi, C. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad177 · Cited by 19
“…2 ( SGLT2 ) may partially overcome this energetic imbalance, especially, but not only, in conditions of insulin resistance or deprivation [ 77 –79 ], through their ketogenic activity [ 80 , 81 ], by providing a convenient way to produce energy [ 73 ], which is not affected by insulin resistance.”
BackgroundMoss, A. S., Dimitropoulos, G., Connolly, D. L., & Lip, G. Y. H. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1350647 · Cited by 15
Ramos, M., Ustyugova, A., Hau, N., & Lamotte, M. (2020) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2020-0071 · Cited by 16
Sorice, G. P., Cinti, F., Leccisotti, L., D’Amario, D., Lorusso, M., Guzzardi, M. A., Mezza, T., Cocchi, C., Capece, U., Ferraro, P. M., et al. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01083-1 · Cited by 16
Sridhar, V. S., Ambinathan, J. P. N., Gillard, P., Mathieu, C., Cherney, D. Z. I., Lytvyn, Y., & Singh, S. K. (2021) · Transplantation · doi:10.1097/tp.0000000000003919 · Cited by 15
Itoh, H., & Tanaka, M. (2022) · Metabolism Open · doi:10.1016/j.metop.2022.100169 · Cited by 16
“Among various hypothesis explaining the reno-protective effects of SGLT2 inhibitors, the “thrifty substrate” hypothesis [80] may support our “greedy” kidney hypothesis.”
BackgroundLiu, H., Sridhar, V. S., Perkins, B. A., Rosenstock, J., & Cherney, D. Z. I. (2022) · Current Diabetes Reports · doi:10.1007/s11892-022-01471-2 · Cited by 14
Metabolic adaptations in pressure overload hypertrophic heart
Wei, J., Duan, X., Chen, J., Zhang, D., Xu, J., Zhuang, J., & Wang, S. (2023) · Heart Failure Reviews · doi:10.1007/s10741-023-10353-y · Cited by 17
“This conflicts with the theory that ketones can restore cardiac metabolic balance presented in the DEFINE-HF trial [188] and contra-dicts the “thrifty fuel hypothesis” [189].”
Effect of Hyperketonemia on Myocardial Function in Patients With Heart Failure and Type 2 Diabetes
Solis‐Herrera, C., Qin, Y., Honka, H., Cersósimo, E., Triplitt, C. L., Neppala, S., Rajan, J., Acosta, F. M., Moody, A. J., Iozzo, P., et al. (2024) · Diabetes · doi:10.2337/db24-0406 · Cited by 14
Kato, K., Suzuki, K., Aoki, C., Sagara, M., Niitani, T., Wakamatsu, S., Yanagi, K., & Aso, Y. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1317748 · Cited by 14
Diabetes medications and cardiovascular outcome trials: Lessons learned
Patel, K. V., Rocha, N. D. A., & McGuire, D. K. (2017) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.84gr.17006 · Cited by 14
Effects of Thiazolidinedione and New Antidiabetic Agents on Stroke
Ahn, C. H., & Lim, S. K. (2019) · Journal of Stroke · doi:10.5853/jos.2019.00038 · Cited by 14
Kalra, S., Aydin, H., Sahay, M., Ghosh, S. K., Ruder, S., TIWASKAR, M. H., Kilov, G., Kishor, K., Nair, T., Makkar, V., et al. (2020) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2020.16.2.113 · Cited by 15
“115 EUROPEAN ENDOCRINOLOGY for the cardiovascular benefit has been termed the ‘thrifty substrate’ hypothesis.(33) Ketones are akin to super food for the cardiac cells and considered superior to fatty acids and glucose for ensuring energy to the ischaemic diabetic myocardium.”
BackgroundFerrannini, G., Savarese, G., & Rydén, L. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108796 · Cited by 14
Albarrán, O. G., Morales, C., Pérez-Maraver, M., Aparicio-Sánchez, J. J., & Simó, R. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01276-2 · Cited by 16
Luong, T. V., Nielsen, E. N., Falborg, L., Kjærulff, M. L. G., Tolbod, L. P., Søndergaard, E., Møller, N., Munk, O. L., & Gormsen, L. C. (2023) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-023-00198-z · Cited by 15
“Ketones have recently been the focus of intensified research due to the possible beneficial cardiovascular and neurological effects associated with hyperketonemia (Ferrannini et al. 2016).”
BackgroundManaging the Course of Kidney Disease in Adults With Type 2 Diabetes: From the Old to the New
Goldenberg, R., Berall, M. J., Chan, C. T., Cherney, D. Z. I., Lovshin, J. A., McFarlane, P. A., Senior, P. A., Verma, S., & Weinstein, J. J. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.06.008 · Cited by 17
Revisiting the Diabetes-Heart Failure Connection
Wallner, M., Eaton, D., von Lewinski, D., & Sourij, H. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1116-z · Cited by 14
Circulating acetoacetate is associated with poor prognosis in heart failure patients
Yokokawa, T., Yoshihisa, A., Kanno, Y., Abe, S., Misaka, T., Yamada, S., Kaneshiro, T., Sato, T., Oikawa, M., Kobayashi, A., et al. (2019) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2019.100432 · Cited by 14
“It has recently been reported that sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) increase circulating ketone bodies and decrease cardiovascular events in patients with diabetes mellitus [17,18].”
BackgroundSchnell, O., Valensi, P. E., Standl, E., & Ceriello, A. (2020) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.129 · Cited by 15
Deberles, E., Maragnès, P., Penniello, M., Allouche, S., & Joubert, M. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2020.04.024 · Cited by 14
Yabiku, K., Nakamoto, K., & Tsubakimoto, M. (2020) · Journal of Diabetes Research · doi:10.1155/2020/1682904 · Cited by 14
“the results of a recent study suggested that ketone bodies might also be involved in the protective effects of SGLT2i [36], which implies that the role of ketone bodies should be further investigated.”
BackgroundThe dual role of empagliflozin: Cardio renal protection in T2DM patients
Shafiq, A., Mahboob, E., Samad, M. A., Rehman, M. H. U., & Tharwani, Z. H. (2022) · Annals of Medicine and Surgery · doi:10.1016/j.amsu.2022.104555 · Cited by 16
“chondria which contributes to the restoration of heart and kidneys [20].”
BackgroundRenal Oxygen Demand and Nephron Function: Is Glucose a Friend or Foe?
Gronda, E., Iacoviello, M., Palazzuoli, A., Benevenuto, M., Gabrielli, D., & Arduini, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24129957 · Cited by 18
SGLT2 inhibitors use in kidney disease: what did we learn?
Akunjee, M., Khosla, S., Nylén, E., & Sen, S. (2025) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00034.2025 · Cited by 17
Cardiovascular and renal benefits of SGLT2 inhibition: insights from CANVAS
Vallon, V., & Thomson, S. C. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.113 · Cited by 15
Echouffo-Tcheugui, J. B., Lewsey, S. C., & Weiss, R. G. (2021) · Journal of Clinical Investigation · doi:10.1172/jci156309 · Cited by 14
Capece, U., Pavanello, C., Cinti, F., Leccisotti, L., Mezza, T., Ciccarelli, G., Moffa, S., Giuseppe, G. D., Soldovieri, L., Brunetti, M., et al. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01491-5 · Cited by 14
BAJAJ, H. S., Aljabri, B. A., & Verma, S. (2018) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000562 · Cited by 14
Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin in a Patient with Colon Malignancy
Papadokostaki, E., & Liberopoulos, E. N. (2019) · Case Reports in Endocrinology · doi:10.1155/2019/3901741 · Cited by 15
“Surprisingly, mild hyperketonemia has been proposed as one of themechanisms responsible for the cardioprotection in the EMPA-REG OUTCOME trial [17].”
BackgroundMilder, T. Y., STOCKER, S. L., Samocha‐Bonet, D., Day, R. O., & Greenfield, J. R. (2019) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-019-02732-y · Cited by 15
Nashawi, M., Sheikh, O., Battisha, A., Ghali, A. N., & CHILTON, R. J. (2020) · Heart Failure Reviews · doi:10.1007/s10741-020-10046-w · Cited by 13
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H., Müller-Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. (2022) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1624-3449 · Cited by 12
Association between Impaired Ketogenesis and Metabolic-Associated Fatty Liver Disease
Bae, J., & Lee, B. (2023) · Biomolecules · doi:10.3390/biom13101506 · Cited by 15
Hou, J., Ren, L., Hou, Q., Jia, X., Mei, Z., Xu, J., Yang, Z., Li, Y., & Yan, C. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1388337 · Cited by 14
“Proposed alternative mechanisms include cardioprotective effects by promotion of ketolysis and ketone body levels (37).”
SGLT2 inhibitors and GLP-1 receptor agonists: a sound combination
Block, C. E. M. D. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30031-7 · Cited by 14
Luong, T. V., Pedersen, M. G. B., Kjærulff, M. L. G., Madsen, S., Lauritsen, K. M., Tolbod, L. P., Søndergaard, E., & Gormsen, L. C. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154862 · Cited by 12
Passantino, A., Rizzo, C., Scrutinio, D., & Palazzuoli, A. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10186-7 · Cited by 13
SGLT-2 Inhibitors: The Next-generation Treatment for Type 2 Diabetes Mellitus
Lukic, N., Mačvanin, M., Gluvic, Z. M., Rizzo, M., Radak, D. J., Suri, J. S., & Isenović, E. R. (2023) · Current Medicinal Chemistry · doi:10.2174/0109298673251493231011192520 · Cited by 16
Acute effects of β-hydroxybutyrate on left ventricular function in young, healthy adults
Oneglia, A. P., Young, B. E., Cipher, D. J., Zaha, V. G., & Nelson, M. D. (2023) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00630.2023 · Cited by 12
Fioretto, P., & Avogaro, A. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1300253 · Cited by 13
The effect of SGLT2 inhibitors on cardiovascular events and renal function
Imprialos, K. P., Stavropoulos, K., Doumas, M. N., Karagiannis, A. I., & Athyros, V. G. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1370371 · Cited by 13
Kinoshita, T., Shimoda, M., Sanada, J., Fushimi, Y., Hirata, Y., Irie, S., Obata, A., Kimura, T., Hirukawa, H., Kohara, K., et al. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0447-8 · Cited by 12
Cessario, J., Pierre-Louis, V., Wahl, J., & Li, Z. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00224-4 · Cited by 13
Sodium-glucose cotransporter 2 inhibition in non-diabetic kidney disease
Almaimani, M. K., Sridhar, V. S., & Cherney, D. Z. I. (2021) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000724 · Cited by 13
Biomolecular Mechanisms of Cardiorenal Protection with Sodium-Glucose Co-Transporter 2 Inhibitors
Prandi, F. R., Barone, L., Lecis, D., Belli, M., Sergi, D., Milite, M., Lerakis, S., Romeo, F., & Barillà, F. (2022) · Biomolecules · doi:10.3390/biom12101349 · Cited by 12
New Oral Hypoglycemic Agents and Cardiovascular Risk. Crossing the Metabolic Border
Dalama, B., & Mesa, J. (2016) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2016.07.008 · Cited by 15
Osataphan, N., Abdel-Qadir, H. M., Zebrowska, A. M., & Borowiec, A. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01577-8 · Cited by 11
“By increasing ketone body production, SGLT2i may enhance cardiac energy metabolism and improved cellular function at mitochondrial level [37].”
Chronic cardiorenal syndrome: cardio-renal protective effect of SGLT2i
Zhu, Y., Lv, C., Yang, H., Lü, Q., Wang, X., Zhang, Y., Guo, M., & Yang, B. (2025) · Renal Failure · doi:10.1080/0886022x.2025.2575921 · Cited by 13
Nuevos hipoglucemiantes orales y riesgo cardiovascular. Cruzando la frontera metabólica
Dalama, B., & Mesa, J. (2016) · Revista Española de Cardiología · doi:10.1016/j.recesp.2016.07.029 · Cited by 12
Dashora, U. K., Gallagher, A., Dhatariya, K., Winocour, P. H., & Gregory, R. (2016) · British Journal of Diabetes · doi:10.15277/bjd.2016.112 · Cited by 12
Effect of Canagliflozin on Heart Function Involving Ketone Bodies in Patients with Type 2 Diabetes
Kutoh, E., & Hayashi, J. (2018) · Drug Research · doi:10.1055/a-0748-5745 · Cited by 11
Depczynski, B., Lee, A. T. K., Varndell, W., & Chiew, A. L. (2019) · Journal of Diabetes Research · doi:10.1155/2019/7387128 · Cited by 11
“An inverted U-shaped relationship between BHB and physiological effects has been proposed with mild elevation being beneficial and higher levels being harmful [23].”
BackgroundSGLT-2 Inhibitors in Heart Failure: Guide for Prescribing and Future Perspectives
Garla, V. V., Butler, J., & Lien, L. F. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01486-3 · Cited by 13
Cardiovascular outcomes in diabetic kidney disease: insights from recent clinical trials
Rocha, N. A., & McCullough, P. A. (2017) · Kidney International Supplements · doi:10.1016/j.kisu.2017.10.004 · Cited by 11
Clinical impact of oral antidiabetic medications in heart failure patients
Palazzuoli, A., Ceccarelli, E., Ruocco, G. M., & Nuti, R. (2018) · Heart Failure Reviews · doi:10.1007/s10741-018-9669-0 · Cited by 12
Lauritsen, K. M., Søndergaard, E., Luong, T. V., Møller, N., & Gormsen, L. C. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa122 · Cited by 11
Hungry Hearts: Energetic Substrate Metabolism in Human Cardiac Hypertrophy and Failure
Bertero, E., Sequeira, V., & Maack, C. (2018) · Circulation Heart Failure · doi:10.1161/circheartfailure.118.005642 · Cited by 14
The use of SGLT2 inhibitors in older people: What is important?
Armentaro, G., Maio, R., Bencivenga, L., Okoye, C., Severini, G., Cassano, V., Zanobbi, V., Condoleo, V., Bellelli, G., Rengo, G., et al. (2025) · Aging Clinical and Experimental Research · doi:10.1007/s40520-025-03156-8 · Cited by 10
“Key pathways include: Metabolic reprogramming [140], Oxidative stress reduction [ 141 ], Autophagy enhancement [142], Sirtuins activation [ 143].”
Sridhar, V. S., Kugathasan, L., Lytvyn, Y., Liu, H., Deng, Y., Lovblom, L. E., Nardone, M., Yuen, D. A., Chen, Y., Hua, J., et al. (2025) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000951 · Cited by 12
Paradigm shift in heart failure treatment: are cardiologists ready to use gliflozins?
Correale, M., Petroni, R., Coiro, S., Antohi, E., Monitillo, F., Leone, M., Triggiani, M., Ishihara, S., Düngen, H., Sarwar, C. M. S., et al. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10107-8 · Cited by 13
Pollock, C. A., & Neuen, B. L. (2021) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2021.02.006 · Cited by 11
Metadata
- Authors
- Ferrannini, E., Mark, M., & Mayoux, E.
- Affiliations
- Istituto di Fisiologia Clinica (IT)
- Boehringer Ingelheim (Germany) (DE)
- Corresponding author
- Ferrannini, Ele
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2016-06-11
- Volume
- 39
- Issue
- 7
- Pages
- 1108-1114
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2412800896
- Cited by
- 975
- References
- 77
- Citations by year
- 2026: 53 · 2025: 53 · 2024: 73 · 2023: 79 · 2022: 91 · 2021: 134 · 2020: 114 · 2019: 100 · 2018: 110 · 2017: 119 · 2016: 47
- FWCI
- 125.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- SGLT2 inhibitors, EMPA-REG OUTCOME trial, cardioprotection, type 2 diabetes, hyperketonemia, beta-hydroxybutyrate, mitochondrial oxygen consumption, hemoconcentration, heart failure, cardiovascular mortality, diabetic heart disease
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Blood Glucose, Blood Pressure, Cardiovascular Diseases, Clinical Trials as Topic, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Glucosides, Heart, Humans, Hypoglycemic Agents, Models, Biological, Research Design, Treatment Outcome, 3-Hydroxybutyric Acid, Sodium-Glucose Transporter 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.